Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KB707

Oncolytic virus · Kills target cells · developed by Krystal Biotech

Phase 1/2 Most advanced trial
KRYS Developer
1 Registered trials

What is KB707?

KB707 is an oncolytic herpes simplex virus type 1 engineered to express the immunostimulatory cytokines IL-2 and IL-12. After intratumoral administration it replicates in tumor cells, causing their lysis and releasing tumor antigens that stimulate a cytotoxic T-lymphocyte response. It is studied in melanoma and cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oncolytic virus
Mechanism
Kills target cells
Pathways
tumor cell lysis, cytotoxic T-lymphocyte response, local cytokine secretion in the tumor microenvironment
Therapy area
Oncology
Developer
Krystal Biotech, Inc. (KRYS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05970497 Phase 1/2 Cancer Recruiting KRYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerCutaneous MelanomaMelanoma Stage IIIMelanoma Stage IV

More from Krystal Biotech

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.

Follow KRYS, the company behind KB707

See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KRYS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.